Seven of the studies [23–29] included advanced NSCLC patients treated with PD-1/PD-LI inhibitors, such as pembrolizumab, nivolumab, or atezolizumab etc., while the other study included patients treated with PD-1/PD-LI inhibitors, CTLA4 inhibitors, or their combination [15]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.